Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

CompletedOBSERVATIONAL
Enrollment

1,851

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

April 30, 2024

Study Completion Date

July 15, 2024

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Cerebrolysin

Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.

Trial Locations (8)

2700

LK Wiener Neustadt, Wiener Neustadt

3100

UK St. Pölten, Sankt Pölten

3300

Landesklinikum Amstetten, Amstetten

3430

UK Tulln, Tulln

4021

Kepler Universitätsklinikum, Linz

5020

CDK Salzburg, Universitätsklinik für Neurologie, Salzburg

6020

Universitätsklinik Innsbruck, Innsbruck

7000

Krankenhaus der Barmherzigen Brüder Eisenstadt, Eisenstadt

Sponsors
All Listed Sponsors
collaborator

IDV Data analysis and study planning Dr. Rahlfs

UNKNOWN

lead

Ever Neuro Pharma GmbH

INDUSTRY

NCT03480698 - Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness | Biotech Hunter | Biotech Hunter